Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA First Amendment meeting

Executive Summary

FDA may hold a public meeting regarding its May 16 request for comments on the agency's commercial speech policy, FDA says in an Aug. 12 letter to Sen. Jack Reed (D-R.I.), who suggested the meeting. "We have not yet decided whether to hold a public meeting or series of meetings on these issues, although that idea is certainly worth considering," the letter says. FDA is accepting comments until Sept. 13, and will accept rebuttal comments until Oct. 28 (1"The Pink Sheet" May 20, p 14)...

You may also be interested in...

FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?

FDA is requesting comment on the legal underpinnings for arguing that promotions of prescription drugs can be more tightly regulated than those for other products

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.

ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts